Apollo Hospitals has reported strong financial results for Q4 FY26, with consolidated revenue reaching ₹66,055 million, an 18% year-on-year increase. Consolidated PAT grew by 36% to ₹5,292 million. For the full year FY26, the company achieved a consolidated revenue of ₹252,285 million, marking a 16% growth, while consolidated PAT rose by 34% to ₹19,415 million, driven by robust performance across its healthcare services, diagnostics, and digital health segments.
Robust Quarterly Performance
Apollo Hospitals demonstrated significant growth in the quarter ending March 31, 2026. The Healthcare Services segment stood out with a revenue of ₹32,678 million, reflecting a 16% growth. The company’s focus on clinical intensity contributed to this performance, with inpatient volumes rising by 7% and average revenue per inpatient growing by 9% to ₹187,208. EBITDA for healthcare services remained strong at ₹7,806 million with a 23.9% margin.
Expansion and Infrastructure Milestones
The company continued its strategic expansion, commissioning four new hospitals in FY26, which added 855 census beds to its network. As of March 31, 2026, the total operational bed capacity stands at 9,620. Apollo has an ambitious roadmap, with a total project cost of approximately ₹8,300 crore, aimed at increasing its total capacity to ~13,100 beds post-expansion. These investments highlight a long-term commitment to enhancing healthcare access across India.
Digital Health and Diagnostics Growth
The Apollo HealthCo segment, encompassing omni-channel pharmacy and the Apollo 24|7 digital platform, reported 20% YoY revenue growth in Q4 to ₹28,482 million. The digital platform now serves 47 million+ registered users and sees ~9 lakh daily active users. Simultaneously, the Diagnostics & Retail Health (AHLL) business saw a strong 24% revenue growth in Q4, supported by a network of 2,501 diagnostics centers and 316 clinics.
Future Strategy
Apollo is moving ahead with its Composite Scheme of Arrangement to streamline its digital and pharmacy businesses. The company expects to achieve an annualized run-rate revenue of INR 250 billion by Q4 FY27, with an EBITDA margin target in the range of 6.5% – 7.0%. This restructuring aims to create an ‘Indian Owned and Controlled Company’ (IOCC) and unlock further value for its shareholders.
Source: BSE
